CoaDATA product list valid from
|
|
|
- Tabitha Bishop
- 5 years ago
- Views:
Transcription
1 Milan Analytica AG Baslerstrasse Rheinfelden ** = Smaller Kit Format specifically designed for Helena C-1/2/4/AC-4 ^ = For use with Helena C-1/2/4/AC-4 CoaDATA product list valid from Product # Product name Approximate number of tests per kit / kit format Coagulation Analysers Helena CoaData 501, 1 channel coagulation analyser (New Edition) 1 Single Cuvette with magnetic stir bar 10 Reagent Container 2 Power adapter 100V - 240V Helena CuvCARD cuvettes with mixer, Dispo-System Thrombi-Tips Racks, 16 x 144 Tips 2304 DPU414-40B External Printer 1 TPR112 Thermo Printer Paper 112 mm (5 rolls) 1 1 / 6
2 Helena CoaData 2001, 2 channel coagulation analyser (New Edition) 1 Single Cuvette with magnetic stir bar 100 Reagent adapter 1 Dust cover 1 CD (Operator's Manual) 1 Thermal printer paper roll Helena CoaData 4001, 4 channel coagulation analyser (New Edition) 1 Single Cuvette with magnetic stir bar 100 Reagent adapter 1 Dust cover 1 CD (Operator's Manual) 1 Thermal printer paper roll 1 Helena CoaDATA 2001, 4001 Consumables: Helena CuvCARD cuvettes with mixer, Dispo-System Thrombi-Tips Racks, 16 x 144 Tips Thermo Printer Paper (10 rolls) ChipCARD Set (7pcs) 1 Haemostasis Reagents Routine Assays Prothrombin Time (PT) Thromboplastin (ISI ~ ) 5265H Thromboplastin LI ** 200 (4 x 2.5 ml) Rabbit Brain Thromboplastin Suspension (liquid) (4 x 2.5 ml) Calcium Chloride Solution 0.025M (liquid) 20 ml working reagent per kit, Low Opacity, Heparin Insensitive (<2U/ml) 5265 Thromboplastin LI 500 (10 x 2.5 ml) Rabbit Brain Thromboplastin Suspension (liquid) (10 x 2.5 ml) Calcium Chloride Solution 0.025M (liquid) 50 ml working reagent per kit, Low Opacity, Heparin Insensitive (<2U/ml) 2 / 6
3 Thromboplastin MI (ISI ~ ) 5274 Thromboplastin MI (5 x 5.0 ml) Thromboplastin Reagent MI (lyophilised) (5 x 5.0 ml) Thromboplastin Diluent (liquid) 25 ml working reagent per kit Activated Partial Thromboplastin Time (APTT) APTT Si L (Micronised Silica Contact Activator) 5562 APTT Si L Minus 500 (5 x 5.0 ml) APTT Si L Minus (liquid) (5 x 5.0 ml) Calcium Chloride Solution 0.025M (liquid) Insensitive to Heparin and low levels of Lupus Anticoagulant 5560 APTT Si L Plus 1000 (5 x 10.0 ml) APTT Si L Plus (lyophilised) (5 x 10.0 ml) Calcium Chloride Solution 0.025M (liquid) Very sensitive to low levels of Lupus Anticoagulant APTT SA (Soluble Ellagic Acid Contact Activator) 5388 APTT SA 500 (5 x 5.0 ml) APTT SA (liquid) (5 x 5.0 ml) Calcium Chloride Solution 0.025M (liquid) APTT ES (Soluble Ellagic Acid Activator with Extra Sensitivity to Heparin and Lupus) 5397H APTT ES ** 500 (5 x 5.0 ml) APTT ES (liquid) (5 x 5.0 ml) Calcium Chloride Solution 0.025M (liquid) Additional Sub-Components 5386 Calcium Chloride (10 x 10.0 ml) Calcium Chloride Solution 0.025M (liquid) 3 / 6
4 Clauss Fibrinogen 5376H Clauss Fibrinogen (5 x 1.0 ml) Thrombin Reagent 100 NIH/ml (lyophilised) (1 x 1.0 ml) Fibrinogen Calibrator (lyophilised) (1 x 25.0 ml) Owren's Veronal Buffer (liquid) (1 x 5.0 ml) Kaolin suspension 0.5g/L (liquid) 5376 Clauss Fibrinogen (5 x 2.0 ml) Thrombin Reagent 100 NIH/ml (lyophilised) (2 x 1.0 ml) Fibrinogen Calibrator (lyophilised) (2 x 25.0 ml) Owren's Veronal Buffer (liquid) (2 x 5.0 ml) Kaolin suspension 0.5g/L (liquid) 5374 Clauss Fibrinogen (Thrombin only) (10 x 2.0 ml) Thrombin Reagent 100 NIH units/ml (lyophilised) 5378 Clauss Fibrinogen (Thrombin only) (10 x 5.0 ml) Thrombin Reagent 100 NIH units/ml (lyophilised) 5379 Fibrinogen Calibrator (10 x 1.0 ml) Fibrinogen Calibrator (lyophilised) 5375 Owren's Buffer (10 x 25.0 ml) Owren's Veronal Buffer (liquid) Kaolin Suspension (1 x 50.0 ml) Kaolin Suspension 0.5 g/l (liquid) Thrombin Clotting Time 5377 Thrombin Time 500 (10 x 5.0 ml) Thrombin Clotting Time Reagent 3 NIH units/ml 5392H Thrombin Time ** 100 (10 x 1.0 ml) Thrombin Clotting Time Reagent 3 NIH units/ml 5392 Thrombin Time 200 (10 x 2.0 ml) Thrombin Clotting Time Reagent 3 NIH units/ml 4 / 6
5 Factor Deficient Plasma Immunodepleted 5790 Factor II Deficient Plasma (Immunodepleted) 200 (10 x 1.0 ml) Immunodepleted Factor II Plasma (lyophilised) 5791 Factor V Deficient Plasma (Immunodepleted) 200 (10 x 1.0 ml) Immunodepleted Factor V Plasma (lyophilised) 5792 Factor VII Deficient Plasma (Immunodepleted) 200 (10 x 1.0 ml) Immunodepleted Factor VII Plasma (lyophilised) 5795 Factor X Deficient Plasma (Immunodepleted) 200 (10 x 1.0 ml) Immunodepleted Factor X Plasma (lyophilised) 5793 Factor VIII Deficient Plasma (Immunodepleted) 200 (10 x 1.0 ml) Immunodepleted Factor VIII Plasma (lyophilised) 5794 Factor IX Deficient Plasma (Immunodepleted) 200 (10 x 1.0 ml) Immunodepleted Factor IX Plasma (lyophilised) 5796 Factor XI Deficient Plasma (Immunodepleted) 200 (10 x 1.0 ml) Immunodepleted Factor XI (lyophilised) 5797 Factor XII Deficient Plasma (Immunodepleted) 200 (10 x 1.0 ml) Immunodepleted Factor XII (lyophilised) Congenital 5191 Factor V Deficient Plasma (Congenital) 200 (10 x 1.0 ml) Congenital Factor V Depleted Plasma (lyophilised) 5192 Factor VII Deficient Plasma (Congenital) 200 (10 x 1.0 ml) Congenital Factor VII Depleted Plasma (lyophilised) 5195 Factor X Deficient Plasma (Congenital) 200 (10 x 1.0 ml) Congenital Factor X Depleted Plasma (lyophilised) 5193 Factor VIII Deficient Plasma (Congenital) 200 (10 x 1.0 ml) Congenital Factor VIII Depleted Plasma (lyophilised) 5194 Factor IX Deficient Plasma (Congenital) 200 (10 x 1.0 ml) Congenital Factor IX Depleted Plasma (lyophilised) 5196 Factor XI Deficient Plasma (Congenital) 200 (10 x 1.0 ml) Congenital Factor XI Depleted Plasma (lyophilised) 5197 Factor XII Deficient Plasma (Congenital) 200 (10 x 1.0 ml) Congenital Factor XII Depleted Plasma (lyophilised) 5 / 6
6 Calibrators and Quality Controls Calibrators 5185 Calibration Plasma (10 x 1.0 ml) Multi-Assayed, Normal Pool Calibration Plasma (lyophilised) 5519 ISI Calibrant Plasma Set (27 x 0.5 ml) ISI Calibrant Plasma (lyophilised) 5379 Fibrinogen Calibrator (10 x 1.0 ml) Clauss Fibrinogen Assayed Normal Pool Calibration Plasma (lyophilised) Controls 5186 Routine Control N (10 x 1.0 ml) Normal Control Plasma Pool, Instrument-Specific Ranges for PT, APTT, Fib, TCT, Antithrombin III (lyophilised) 5187 Routine Control A (10 x 1.0 ml) Mild Abnormal Control Plasma Pool, Instrument-Specific Ranges for PT, APTT, Fib, TCT, Antithrombin III (lyophilised) 5183 Routine Control SA (10 x 1.0 ml) Severe Abnormal Control Plasma Pool,Instrument-Specific Ranges for PT, APTT, Fib, TCT, Antithrombin III (lyophilised) 5482 Routine Coagulation Control Set (4 x 1.0 ml) Routine Control N (3 x 1.0 ml) Routine Control A (3 x 1.0 ml) Routine Control SA 5301 Speciality Assayed Control N (10 x 1.0 ml) Speciality Assayed Normal Control Plasma Pool (lyophilised) 5302 Speciality Assayed Control A (10 x 1.0 ml) Speciality Assayed Abnormal Control Plasma (lyophilised) INR Reference Set 5490 INR Reference Set 4 x (3 x 1.0 ml) INR Reference Plasma (lyophilised) 6 / 6
Automated Coagulation Analyser product list 2018
Milan Analytica AG Baslerstrasse 15 4310 Rheinfelden www.milananalytica.ch ** = Smaller Kit Format specifically designed for Helena C-1/2/4/AC-4 ^ = For use with Helena C-1/2/4/AC-4 Automated Coagulation
Haemostasis Reagents product list 2018
Milan Analytica AG Baslerstrasse 15 4310 Rheinfelden www.milananalytica.ch Product # ** = Smaller Kit Format specifically designed for Helena C-1/2/4/AC-4 ^ = For use with Helena C-1/2/4/AC-4 Product name
Diagnosing Haemostasis PRODUCT CATALOG
Diagnosing Haemostasis PRODUCT CATALOG CONTENTS MTI COAGULATION ANALYZER MT1C- Single Channel Semi Automated Coagulation Analyzer MT4C- Four Channel Semi Automated Coagulation Analyzer Bera - New Generation
With Stago, discover an outstanding Routine range
In Haemostasis, There s routine... and then there s Routine With Stago, discover an outstanding Routine range An optimal Routine range for guaranteed satisfaction 1 Comprehensive range Stago s extensive
Product Catalogue
1 www.hartbio.co.uk www.thrombistat.co.uk Product Catalogue 2 Hart Biologicals is pleased to present its products and services Product Catalogue Hart Biologicals was founded in 2002 and is located in the
Product Catalogue
1 www.hartbio.co.uk www.thrombistat.co.uk Product Catalogue 2 Hart Biologicals is pleased to present its products and services Product Catalogue Hart Biologicals was founded in 2002 and is located in the
2015 Catalogue Coagulation
2015 Catalogue Coagulation 1 CONTENTS Reagents TriniCLOT TM Routine Reagents PT 4 aptt 4 Fibrinogen 5 Thrombin Time 5 Factor Deficient Plasmas 5 Solutions 5 TriniLIA TM D-Dimer TriniLIA TM D-Dimer 6 TriniCLOT
PROTHROMBIN TIME WHY USE LOW ISI (HIGH SENSITIVITY)
PROTHROMBIN TIME WHY USE LOW ISI (HIGH SENSITIVITY) PROTHROMBIN TIME DEFINITION The Prothrombin time is the functional determination of the extrinsic coagulation pathway. It is a widely used laboratory
Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.
Test Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Karen A. Moffat BEd, MSc, ART, FCSMLS(D) Technical Specialist, Coagulation, HRLMP Assistant Professor, Department of
Bench top / Desktop. English HumaClot Pro GUI. Open at launch, but system will be closed mandatorily in the future.
Specifications & more HumaClot Pro > > System Specifications > > Scope of Supply > > Obligatory Items > > Optional Items System Overview Cat.No. 15800 Analyzer type Fully automated coagulation analyzer
Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues
Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues Kristi J. Smock, MD Associate Professor of Pathology University of Utah Health Sciences Center Medical Director, Hemostasis/Thrombosis
Coagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117
www.cap.org Coagulation Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Serviced (CMS). Coagulation Limited CGL, CGDF Analyte CGL CGDF New
More to Life. Where research becomes the basis of discovering newer ways of alleviating human suffering and empowering an individual with good health.
More to Life Where research becomes the basis of discovering newer ways of alleviating human suffering and empowering an individual with good health. Meril Diagnostics Emerging from a lineage of successful
Sysmex Educational Enhancement & Development
Sysmex Educational Enhancement & Development SEED-Africa Newsletter No 9 2011 Quality control in coagulation testing Basic Coagulation The purpose of this newsletter is to provide an overview of internal
Critical aspects in routine coagulation testing
Pure & Appl. Chem., Vol. 68, No. 10, pp. 1867-1871,1996, Printed in Great Britain. 0 1996 IUPAC Critical aspects in routine coagulation testing A. D'Angelo, P. Della Valle, L. Crippa, E. Pattarini, S.
R.Li, C.Swaelens, F.Vandermijnsbrugge, B.Cantinieaux BSTH Laboratory of haematology, Porte de Hal,
Institut J. Bordet Normal with Actin-FS avoids intrinsic pathway factors assays in the presence of an isolated prolongation of (Platelin-LS) without hemorrhagic history R.Li, C.Swaelens, F.Vandermijnsbrugge,
Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors
Hemostasis Hemostasis ( hemo =blood; sta= remain ) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help
Note: The taller 100 x 13 mm tube is not designed to run on the ACL TOP. Plasma after centrifugation of these tubes must be placed in sample cups.
Created Revised Reviewed Approved Lupus Insensitive aptt on the ACL TOP HEM 4.15.1 7/13/2012 4/11/2013 4/11/2013 4/11/2013 I. PRINCIPLE The activated partial thromboplastin time is a global screening procedure
Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1
Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1 Donna D. Castellone, MS, MT (ASCP) SH Clinical Project Manager Hematology and Hemostasis Siemens Healthcare Diagnostics Disclosures
General Principles of. Hemostasis. Kristine Krafts, M.D.
General Principles of Hemostasis Kristine Krafts, M.D. Hemostasis is a balancing act! pro-ting plugs up holes in blood vessels anti-ting keeps ting under control Pro-Clotting Pro-Clotting vessels platelets
COAGULATION CONTROL - LEVEL 3 (COAG CONTROL 3)
COAGULATION CONTROL - LEVEL 3 (COAG CONTROL 3) Cat No. CG5023 Lot No. 182CG Size: 12 x 1 ml Expiry: 2018-03 INTENDED USE This product is intended for in vitro diagnostic use, and in the quality control
LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY
LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency
Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016
Laboratory investigation in the Bleeding Patient Dr Craig Taylor Consultant Haematologist May 2016 Introduction Bleeding is common May consume significant resources Crossmatched blood Lab results may be
73 Coagulation Laboratory: Methods, Standards and Cost Effective Testing (Part 1) Donna Castellone MS, MT(ASCP)SH
73 Coagulation Laboratory: Methods, Standards and Cost Effective Testing (Part 1) Donna Castellone MS, MT(ASCP)SH 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe,
Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc All rights reserved.
Excel with Confidence Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc. 2015 All rights reserved. General Lab Challenges Test Volume Financial Performance Accuracy Reliability
Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?
Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective? Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia
Coagulation in perspective: Blood management. Objectives
Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.
UK NEQAS FOR BLOOD COAGULATION: Programmi EQAS nel laboratorio di coagulazione
UK NEQAS FOR BLOOD COAGULATION: Programmi EQAS nel laboratorio di coagulazione Tim Woods, Manager UK NEQAS for Blood Coagulation STH Royal Hallamshire Hospital Sheffield U.K. www.ukneqasbc.org Quality
Coagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen.
Coagulation Cascade Intrinsic Pathway Extrinsic Pathway Contact Activation XIIa XI XIa Prekallikrein HMW Kininogen IX IXa Ca 2+ Anticoagulation proteins: Protein C, Protein S, Antithrombin III, TFPI TF
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask
BNL Haemostasis. Catalogue
2017 BNL Haemostasis Catalogue Haemoscore, ihemostasis Discover the New Stago Applications! Sum mary SYSTEMS STA R Max 2 System 6 STA Compact Max 2 System 8 STart Max System 10 STA Satellite USB System
TRUSTED PARTNER TO PRODUCT CATALOG. Platelet Aggregation. Reagents. Clinical Trials. Technical Literature. Product Support & Services
PRODUCT CATALOG Platelet Aggregation Reagents Clinical Trials Technical Literature Product Support & Services TRUSTED PARTNER TO 5 of the Top 7 Clinical Research Organizations 4 of the Top 5 Reference
Pearls and Pitfalls in Factor Inhibitor Testing
Pearls and Pitfalls in Factor Inhibitor Testing Dorothy M. Adcock M.D. Esoterix Coagulation, Laboratory Corporation of America Holdings ISLH May 19, 2015 Outline Overview of coagulation factor inhibitors
DOAC s and Implications on Laboratory Results. Kandice Kottke-Marchant, MD, PhD Cleveland Clinic
DOAC s and Implications on Laboratory Results Kandice Kottke-Marchant, MD, PhD Cleveland Clinic Anticoagulants Heparin Low Molecular Weight Heparins enoxaparin, fragmin Heparin pentasaccharide - fondaparinux
Simple screening tests for the diagnosis of isolated
J. clin. Path., 1975, 28, 524-530 Simple screening tests for the diagnosis of isolated clotting factor defects With special reference to 'contact factor' defects G. I. C. INGRAM, S. F. KNIGHTS, C. L. AROCHA-PINANGO,
Please note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test.
Please note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test. In the US, the product is intended For Research Use Only.
Marcia L. Zucker, Ph.D. ZIVD LLC
Marcia L. Zucker, Ph.D. ZIVD LLC 1 Monitoring hemostasis Bleeding Clotting 2 Picture courtesy of Helena Laboratories 3 Extrinsic Pathway Monitor with ACT / aptt WARFARIN Monitor with PT Common Pathway
Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis
Haemostasis Haemostasis The function of haemostasis is: to prevent blood loss from injured vessels to stop bleeding to prevent thrombosis Haemostasis blood endothelium basement membrane subendothelium
Haemostasis Laboratory, University of Glasgow, Glasgow Royal Infirmary. Prepared by Ann Rumley, Estelle Poorhang. 03/05/05
Haemostasis Laboratory, University of Glasgow, Glasgow Royal Infirmary. Prepared by Ann Rumley, Estelle Poorhang. 03/05/05 Standard Operating Procedure for Determination of clottable (Clauss) fibrinogen
Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation
Laboratory Investigation of Challenging Cases Laura A. Worfolk, Ph.D Scientific Director, Coagulation Coagulation Cascade XII XIIa XI HMWK/Prekallikrein XIa VII Injury IX X IXa VIII Xa X TF TF/VIIa Prothrombin
Customer Service. For further product information, technical advice, prices or to place an order contact. Phone:
Customer Service For further product information, technical advice, prices or to place an order contact Phone: + 43 1 86373-0 Fax: + 43 1 86373-44 Sales: sales@technoclone.com Product Support: products@technoclone.com
Stability of Plasma for Add-On PT and APTT Tests
COAGULATION AND TRANSFUSION MEDICINE Original Article Stability of Plasma for Add-On PT and APTT Tests DEMETRA NEOFOTISTOS, MT, MARIA OROPEZA, MT(ASCP), AND CHUNG-HSIN TS'AO, PhD We conducted studies to
Current laboratory practices in the diagnosis and management of haemophilia
Current laboratory practices in the diagnosis and management of haemophilia Marc Jacquemin University of Leuven BSTH 2013 Detection of severe haemophilia A Validation of the FVIII assay for the detection
TSOAC Case Study 1. Question. TSOAC Case Study 1 Continued
TSOAC Case Study 1 An otherwise healthy 56-year-old man presents to the emergency department with left leg pain and swelling for the last 3 days. Compression ultrasonography confirms left common femoral
These slides and the data they contain are the sole property of the author(s) of the slide set.
These slides and the data they contain are the sole property of the author(s) of the slide set. Reproduction or distribution of the content of the slides or the data they contain requires the prior, specific
Coagulation Mechanisms Dr. Nervana Bayoumy
Coagulation Mechanisms Dr. Nervana Bayoumy Associate Professor Department of Physiology Objectives At the end of this lecture you should be able to: 1. Recognize the different clotting factors 2. Understand
UW Medicine Alternative Monitoring for Antithrombotic Agents
Tags: monitoring alternative monitoring SUMMARY OF ANTICOAGULATION LAB TESTS AT UWMedicine Description Order Code Specimen Collection Availability Turn-Around Time Anti Xa Based Tests antixa for heparin
The Comprehensive and Efficient Solution. for Your Hemostasis Lab. Hemostasis System
The Comprehensive and Efficient Solution for Your Hemostasis Lab Hemostasis System Hemostasis System Autodilution Perform in-line or with a secondary cup, based on required dilution for assay Random Programming
DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK
DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK 11794-8205 COAGULATION COMPETENCY EVALUATION FORM STUDENT NAME:
Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:
Special Coagulation - APC Resistance DiaPharma Group, Inc. Customer Service: 1.800.526.5224 Technical Support:1.800.447.3846 www.diapharma.com 1 Review of Hemostasis Overview Pathways of coagulation, anticoagulation,
QUICK USER GUIDE CAPILLARY BLOOD INR TESTING FOR USING THE THROMBI-STAT MC1 WB INSTRUMENT MANCHESTER CAPILLARY REAGENT INTRODUCTION AND
QUICK USER GUIDE FOR CAPILLARY BLOOD INR TESTING USING THE THROMBI-STAT MC1 WB INSTRUMENT AND MANCHESTER CAPILLARY REAGENT INTRODUCTION The combination of the Hart Biologicals Thrombi-stat MC1WB coagulation
Schedule of Accreditation
Schedule of Accreditation Organisation Name INAB Reg No Contact Name Address West North West Hospitals Group Galway University Hospital Dept Haematology 239MT Mary Kilcooley Contact Phone No 091 544419
F11 (Human) ELISA Kit
F11 (Human) ELISA Kit Catalog Number KA1400 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay... 3 General Information...
NEW! Introducing Simple, Comprehensive Solutions. of the ACL TM Family. New Members. Innovation. Leadership. Commitment.
NEW! Introducing Simple, Comprehensive Solutions New Members of the ACL TM Family Innovation. Leadership. Commitment. New Members of the ACL Family Introducing Simple, Comprehensive Solutions for the Hemostasis
Development of a Novel Automated Screening Method for Detection of FVIII Inhibitors
Development of a Novel Automated Screening Method for Detection of FVIII Inhibitors Matthew S. Evans, MD Assistant Professor of Hematology and Pathology Department of Hematology Hemophilia Treatment Center
COMPANY WITH QUALITY MANAGEMENT SYSTEM CERTIFIED BY DNV GL = ISO 9001 = Thrombin Generation Assay. Kit Insert
COMPANY WITH QUALITY MANAGEMENT SYSTEM CERTIFIED BY DNV GL = ISO 9001 = Thrombin Generation Assay Kit Insert Version: February 2018 Summary Thrombin is a key enzyme of the coagulation cascade. Its measurement
Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system
Primary hemostasis Vascular endothelium Vasoconstriction : local tissue factor, nervous system Platelet Plug Platelet Adhesion Platelet Activation Platelet Aggregation Platelet Plug Formation Secondary
Type of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis.
Coagulation disorders induced by L-asparaginase: correction with and without fresh-frozen plasma Glasmacher A, Kleinschmidt R, Unkrig C, Mezger J, Scharf R E Record Status This is a critical abstract of
Table of Contents. Introduction. Worldwide Market and Technology Overview
Table of Contents Introduction Worldwide Market and Technology Overview A. Major Routine and Special Coagulation Tests 1. Introduction 2. Activated Partial Thromboplastin Time (APTT) 3. Alpha-2 Antiplasmin
SEED Coagulation. Sysmex Educational Enhancement and Development April 2014
SEED Coagulation Sysmex Educational Enhancement and Development April 2014 The Thrombin Time Test and Reptilase Test what is their role in coagulation testing? Baseline screening tests of coagulation The
Managing the Risks Associated with Anticoagulant Therapy. Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde
Managing the Risks Associated with Anticoagulant Therapy Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde Background Identified as high risk medicines Wide range
Comparison of Several Activated Partial Thromboplastin Time Methods
Comparison of Several Activated Partial Thromboplastin Time Methods ROBERT J. MOWN, M.D., AND DOROTHY WILLOUGHBY, B.S., M.T. (ASCP) Department of Pathology, Harbor General Hospital, UCLA School of Medicine,
Effect of Direct Thrombin Inhibitors, Bivalirudin, Lepirudin, and Argatroban, on Prothrombin Time and INR Values
Coagulation and Transfusion Medicine / DIRECT THROMBIN INHIBITOR EFFECT ON INR Effect of Direct Thrombin Inhibitors, Bivalirudin, Lepirudin, and Argatroban, on Prothrombin Time and INR Values Robert C.
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Haematology Pathology Centre C37 New Cross Hospital Wolverhampton Road Wolverhampton WV10 0QP United Kingdom Contact: Katy New
Upon completion of the Clinical Hematology rotation, the MLS student will be able to:
Clinical Performance Objectives in Clinical Hematology Department of Medical and Research Technology University of Maryland School of Medicine Spring 2015 Upon completion of the Clinical Hematology rotation,
Postpartum Haemorrhage make sure you give enough fibrinogen!
Postpartum Haemorrhage make sure you give enough fibrinogen! Disclaimer / Pre-amble These cases have been de-identified to protect the identity of the patient and the treating teams. These are all real
Sysmex Educational Enhancement and Development No
SEED Haematology Sysmex Educational Enhancement and Development No 3 2014 The Thrombin Time test and Reptilase test what is their role in coagulation testing? The purpose of this newsletter is to provide
Clotting tests. June 2009 V Diagnostica Stago - All right reserved
7 Clotting tests June 2009 V2 Reagents Technologies Clotting tests Chromogenic assays Enzyme Immuno Assays (ELISA) Latex Immuno Assays (LIA) Latex slide agglutination Flow cytometry 2 Clotting tests Samples
Basic coagulation applications and case studies
Basic coagulation applications and case studies Jing Jin Clinical laboratory Scientist (MLS, ASCP) - Coagulation/Hematology Stanford University Hospital and Clinics 1 Agenda Overview about 3 major phases
2 Thomas G. DeLoughery
Tests of Hemostasis and Thrombosis 2 Thomas G. DeLoughery A routine laboratory test once well-established is often slavishly adhered to, with little further thought about how it originated, why it is done
Laboratory Monitoring of Anticoagulation
Michael Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Learning Objectives Explain the role of common laboratory tests used in monitoring of anticoagulation therapy.
Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO
Introduction Hemostasis: Tourniquet Test & Bleeding Time Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Hemostasis A series of reactions that function to stop bleeding, maintaining
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Haematology Department Contact: Ian Diton Conquest Hospital Tel: +44 (0) 1323 417400 ex 4127 The Ridge E-Mail: ian.diton@nhs.net St Leonards
Management & Administration
Laboratory Evaluation of the STA Satellite Benchtop Coagulation Instrument Ha T Su, MT(ASCP) CM, 1 Katherine L Whelchel, MT(ASCP)SH, 2 Mary Jo Sonnek, MT(ASCP), 1 and Gwyn A. Cutsforth, PhD 2 * ABSTRACT
Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications
Thromboelastography (TEG): Basics & Clinical Applications Paula J. Santrach MD Associate Professor, Laboratory Medicine Mayo Clinic Rochester, MN Disclosures Relevant financial relationships NONE Off label
Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017
Apheresis Anticoagulant Removal Oluwatoyosi Onwuemene, MD MS May 6th, 2017 Talk Outline Case presentation Factors associated with drug removal TPE s effects on hematologic parameters Anticoagulant properties
Falsely Elevated INR Results Due to the Sensitivity of a Thromboplastin Reagent to Heparin
COAGULATION AND TRANSFUSION MEDICINE Falsely Elevated INR Results Due to the Sensitivity of a Thromboplastin Reagent to Heparin BRENDA F. LEECH, RT, 1 AND CEDRIC J. CARTER, MB, FRCP 2 The aim of this study
Enzyme Research Laboratories product list 2018
Milan Analytica AG Baslerstrasse 15 4310 Rheinfelden Switzerland www.milananalytica.ch Enzyme Research Laboratories product list 2018 Product # Sizes/quantity Human Proteins Human Prothrombin Prothrombin
Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1
Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1 Learning Objectives Explain the concept of thrombophilia Recognize
Clumsy Coagulation Communication
Clumsy Coagulation Communication Let s Blame the Lab! Lab Clinician Communication Barriers and opportunities Where are the errors made? How do we enhance patient experience? George A Fritsma MS, MLS, Your
Stago Newsletter. Diagnostica Stago Pty Ltd 651 Doncaster Road Doncaster, Vic Phone:
Diagnostica Stago Pty Ltd 651 Doncaster Road Doncaster, Vic 3108 Phone: +61 3 9840 5555 E-mail: info@stago.com Stago Newsletter V O L U M E 1, I S S U E 2 A U G U S T 2 0 1 0 I N S I D E T H I S I S S
WORTHAM LABORATORIES, INC. DRAFT Thrombin Reagent
WORTHAM LABORATORIES, INC. DRAFT Thrombin Reagent Intended Use Wortham Laboratories Thrombin Reagent is intended for thrombin to convert fibrinogen in the quantitative determination of fibrinogen in plasma
Hemostasis. Catalogue
2017 Hemostasis Catalogue Haemoscore, ihemostasis Discover the New Stago Applications! Table of Contents SYSTEMS STA R Max...1 STA Compact Max...3 STA Satellite USB System...5 STart System...7 CAT System
EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 Proposed WHO Reference Reagent for Activated Blood Coagulation Factor X (FXa), Human Craig Thelwell 1, John Hogwood
Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular
Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108
A Accuracy, 6, 7, 15, 46, 52, 53, 61, 75, 100, 143, 144, 149, 166, 176, 178 Acquired coagulation disorders, 111 115 Acquired platelet disorders, 99 108 ACT. See Activated clotting time (ACT) Activated
K. Doubleday S. Kumnick. Clot Signature Curves and the ACLAdvance TM
COAGULATION 12 K. Doubleday S. Kumnick Clot Signature Curves and the ACLAdvance TM K. Doubleday S. Kumnick Clot Signature Curves and the ACL Advance TM Index 3 What is a Clot Signature Curve Pag. 5 How
The International Haemostasis External Quality Control Program
The International Haemostasis External Quality Control Program Intended use of Quality Control Primary Purpose of the Clinical Laboratory To produce accurate results that will correctly diagnose and interpret
ANTITHROMBIN FACTOR Xa
2014 ATITRMBI FACTR Xa The Coamatic Antithrombin kits are simple, accurate and convenient. All methods are based on inhibition. Allows accurate determination of antithrombin in patients receiving heparin
Prothrombin time derived fibrinogen determination on Sysmex CA-6000
462 Haemostasis Research Unit, Department of Haematology, University College London, London, UK ASLawrie S J McDonald G Purdy I J Mackie S J Machin Correspondence to: Dr A S Lawrie, Haemostasis Research
HEMOCHRON. Whole Blood Coagulation Systems
HEMOCHRON Whole Blood Coagulation Systems Activated Partial Thromboplastin Time (APTT) Cuvette Correlation Protocol for HEMOCHRON Microcoagulation Instruments MSIG: 49 10/06 Dear Medical Professional:
Virtual Lectures Planning Committee Disclosure Summary
Mayo Medical Laboratories Virtual Lectures 2014 MFMER MFMER Virtual Lectures Planning Committee Disclosure Summary As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CPD)
Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation
Laboratory Investigation of Challenging Cases Laura A. Worfolk, Ph.D Scientific Director, Coagulation Disclosures Employee of Quest Diagnostics Case focus: Importance of knowing test limitation/interpretations
Enzymatic Assay of HIRUDIN 1. Hirudin + Thrombin > Hirudin/Thrombin complex + Thrombin (excess)
Enzymatic Assay of HIRUDIN 1 PRINCIPLE: Hirudin + Thrombin > Hirudin/Thrombin complex + Thrombin (excess) Plasma (Fibrinogen) Thrombin (excess) > Clot (Fibrin) CONDITIONS: T = 37 C, ph = 7.35 METHOD: Fibrometer
The Coagulation Workup In The Office Setting
CAA Conference alm Springs 2012 The Coagulation Workup In The Office Setting CAA Conference alm Springs, October 2012 Robert Miller, A-C Henoch-Schoenlein urpura 1 CAA Conference alm Springs 2012 2 CAA
Category Storage Shelf Life Additional Criteria
CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.
The partial thromboplastin (cephalin) time test
J. clin. Path., 1972, 25, 1038-10 The partial thromboplastin (cephalin) time test L. POLLER AND JEAN M. THOMSON From the National Thromboplastin Centre, and the Haematology Department, Withington Hospital,